Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, V L M Road, Vile Parle (w), Mumbai, 400056, India.
Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, V L M Road, Vile Parle (w), Mumbai, 400056, India.
Eur J Pharmacol. 2024 Oct 15;981:176868. doi: 10.1016/j.ejphar.2024.176868. Epub 2024 Aug 10.
Anxiety and depression are central nervous system illnesses that are among the most prevalent medical concerns of the twenty-first century. Patients with this condition and their families bear psychological, financial, and societal hardship. There are currently restrictions when utilizing the conventional course of treatment. RNA interference is expected to become an essential approach in anxiety and depression due to its potent and targeted gene silencing. Silencing of genes by post-transcriptional modification is the mechanism of action of small interfering RNA (siRNA). The suppression of genes linked to disease is typically accomplished by siRNA molecules in an efficient and targeted manner. Unfavourable immune responses, off-target effects, naked siRNA instability, nuclease vulnerability, and the requirement to create an appropriate delivery method are some of the challenges facing the clinical application of siRNA. This review focuses on the use of siRNA in the treatment of anxiety and depression.
焦虑和抑郁是中枢神经系统疾病，是 21 世纪最普遍的医学关注点之一。患有这种疾病的患者及其家属承受着心理、经济和社会的困难。目前在利用传统治疗方法时存在限制。由于 RNA 干扰具有强大且靶向的基因沉默作用，预计它将成为焦虑和抑郁治疗的重要方法。小干扰 RNA（siRNA）通过转录后修饰来实现基因沉默。siRNA 分子通常以高效和靶向的方式抑制与疾病相关的基因。siRNA 面临的挑战包括免疫反应不良、脱靶效应、裸露 siRNA 不稳定性、核酸酶易感性以及需要创建适当的传递方法。本综述重点介绍了 siRNA 在焦虑和抑郁治疗中的应用。
